☆ 4.5 Article

Determination of optimum number of cycles of induction chemotherapy for locoregionally advanced nasopharyngeal carcinoma: a single-center retrospective study

EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY (2023)

Related references

Note: Only part of the references are listed.

Article Oncology

Optimize the number of cycles of induction chemotherapy for locoregionally advanced nasopharyngeal carcinoma: a propensity score matching analysis

YuTing Jiang et al.

Summary: This study assessed the efficiency and acute toxicities of different cycles of induction chemotherapy for patients with locoregionally advanced nasopharyngeal carcinoma. The results showed that two cycles and three cycles of induction chemotherapy had similar survival outcomes, but three cycles had a higher incidence of treatment-related acute toxicity.

JOURNAL OF CANCER (2022)

Add to Collection

Article Medicine, General & Internal

Induction chemotherapy regimen of docetaxel plus cisplatin versus docetaxel, cisplatin plus fluorouracil followed by concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: Preliminary results of an open-label, noninferiority, multicentre, randomised, controlled phase 3 trial

Yan Wang et al.

Summary: This study aimed to evaluate the noninferiority of docetaxel plus cisplatin (TP) induction chemotherapy regimen compared to docetaxel plus cisplatin plus fluorouracil (TPF) regimen in patients with locoregionally advanced nasopharyngeal carcinoma (LA-NPC). The study showed that TP induction chemotherapy regimen was noninferior to TPF regimen in terms of failure-free survival, with fewer side effects.

ECLINICALMEDICINE (2022)

Add to Collection

Review Oncology

Advanced Nasopharyngeal Carcinoma: Current and Emerging Treatment Options

Rina Jiromaru et al.

Summary: Nasopharyngeal carcinoma (NPC) has shown improved treatment outcomes in recent years, but advanced stages still carry a poor prognosis. Chemoradiotherapy is the main treatment option, along with platinum-based chemotherapy. Immunotherapy, especially immune checkpoint inhibitors, is being explored as a potential treatment for recurrent or metastatic NPC. Future trends in NPC treatment include risk classification based on plasma EBV-DNA levels and personalized therapy selection.

CANCER MANAGEMENT AND RESEARCH (2022)

Add to Collection

Article Oncology

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Hyuna Sung et al.

Summary: The global cancer burden in 2020 saw an estimated 19.3 million new cancer cases and almost 10.0 million cancer deaths. Female breast cancer surpassed lung cancer as the most commonly diagnosed cancer, while lung cancer remained the leading cause of cancer death. These trends are expected to rise in 2040, with transitioning countries experiencing a larger increase compared to transitioned countries due to demographic changes and risk factors associated with globalization and a growing economy. Efforts to improve cancer prevention measures and provision of cancer care in transitioning countries will be crucial for global cancer control.

CA-A CANCER JOURNAL FOR CLINICIANS (2021)

Add to Collection

Article Oncology

The Chinese Society of Clinical Oncology (CSCO) clinical guidelines for the diagnosis and treatment of nasopharyngeal carcinoma

Ling-Long Tang et al.

Summary: The Chinese Society of Clinical Oncology (CSCO) formed a multidisciplinary team to develop comprehensive guidelines for the diagnosis and management of nasopharyngeal carcinoma (NPC) in order to improve the management of NPC.

CANCER COMMUNICATIONS (2021)

Add to Collection

Article Otorhinolaryngology

Optimizing number of cycles of induction chemotherapy for patients with nasopharyngeal carcinoma: Retrospective survival analysis

Yan He et al.

HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK (2020)

Add to Collection

Review Medicine, General & Internal

Nasopharyngeal carcinoma

Yu-Pei Chen et al.

LANCET (2019)

Add to Collection

Article Medicine, General & Internal

Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma

Yuan Zhang et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Add to Collection

Article Oncology

Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: A phase III multicentre randomised controlled trial

Su-Mei Cao et al.

EUROPEAN JOURNAL OF CANCER (2017)

Add to Collection

Article Oncology

Association of the neoadjuvant chemotherapy cycle with survival outcomes in patients with locoregionally advanced nasopharyngeal carcinoma: a propensity-matched analysis

Wang Fangzheng et al.

ONCOTARGET (2017)

Add to Collection

Article Oncology

Addition of 5-fluorouracil to first-line induction chemotherapy with docetaxel and cisplatin before concurrent chemoradiotherapy does not improve survival in locoregionally advanced nasopharyngeal carcinoma

Wang Fangzheng et al.

ONCOTARGET (2017)

Add to Collection

Article Oncology

Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial

Ying Sun et al.

LANCET ONCOLOGY (2016)

Add to Collection

Article Oncology

Optimize the cycle of neoadjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma treated with intensity-modulated radiotherapy: A propensity score matching analysis

Hao Peng et al.

ORAL ONCOLOGY (2016)

Add to Collection

Article Oncology

Neoadjuvant Chemotherapy Followed by Concurrent Chemoradiation for Locoregionally Advanced Nasopharyngeal Carcinoma Interim Results From 2 Prospective Phase 2 Clinical Trials

Lin Kong et al.

CANCER (2013)

Add to Collection

Article Oncology

Experience with combination of docetaxel, cisplatin plus 5-fluorouracil chemotherapy, and intensity-modulated radiotherapy for locoregionally advanced nasopharyngeal carcinoma

Chengrun Du et al.

INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2013)

Add to Collection

Article Oncology

Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial

Lei Chen et al.

LANCET ONCOLOGY (2012)

Add to Collection

Article Oncology

Phase II study of docetaxel, cisplatin, and 5-FU induction chemotherapy followed by chemoradiotherapy in locoregionally advanced nasopharyngeal cancer

Woo Kyun Bae et al.

CANCER CHEMOTHERAPY AND PHARMACOLOGY (2010)

Add to Collection

Article Oncology

Randomized Phase II Trial of Concurrent Cisplatin-Radiotherapy With or Without Neoadjuvant Docetaxel and Cisplatin in Advanced Nasopharyngeal Carcinoma

Edwin P. Hui et al.

JOURNAL OF CLINICAL ONCOLOGY (2009)

Add to Collection

Article Oncology

Overall survival after concurrent cisplatin-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma

ATC Chan et al.

JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)

Add to Collection

Article Oncology

Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: Positive effect on overall and progression-free survival

JC Lin et al.

JOURNAL OF CLINICAL ONCOLOGY (2003)

Add to Collection

Article Oncology

Concurrent chemotherapy-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: Progression-free survival analysis of a phase III randomized trial

ATC Chan et al.

JOURNAL OF CLINICAL ONCOLOGY (2002)

Add to Collection

© Peeref 2019-2024. All rights reserved.